| | |
Good morning, 360! | Just 12 seats left in Jason's newest Small Account Journey special — grab one now. And don't forget to join us today for LIVE trading all day. Be the best prepared trader on the Street! | | FOCUS LIST🔎 | RNLX - Up over 50% in the pre-market after announcing collaboration with Steno Diabetes Center to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD) in first expansion for KidneyIntelX platform beyond US | CYN - Up over 40% in pre after announcing the expansion of its dealer network to include Alta Equipment Group, a company with more than $1bn in annual sales | QS - Up over 40% in pre after agreement with Volkswagen's battery unit PowerCo to massively ramp up production of solid-state batteries pending technological progress and certain royalty payments | | *sponsored by Sica Media | Pull up Citius Pharmaceuticals (CTXR) right now. | There aren't many stocks with this kind of momentum right now. | Since last week's low, CTXR has managed to rally over 50% higher. | What I like best is that this didn't happen all in one day. This has been a gradual buildup of upward pressure on the stock over several days, with "smaller" gains of around 10% a day. | Check out this chart and see what I mean…. | | I don't like to speculate too much, but when I see a massive volume bar on a down day like we saw on CTXR last week, that is typically very close to the "panic lows." | At the "panic lows," all the sellers tend to be exhausted. | At the same time, there are usually a ton of short sellers who have bet the stock would go lower (and they are usually right!). But, shorts have to cover their positions at some time. | Together this can create a very good buying opportunity. | I think that is a very acute possibility with CTXR right now. | We might be seeing a short squeeze in the works, and if that happens, who knows where it could go? | For my full report, see HERE. | And no matter what you do, it is very important to approach each trade you make with a solid game plan that keeps your risk to a minimum and enables you to capture profits if they appear. | *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
|
| | HOTLIST🔥 | RNLX - Up over 50% in the pre-market after announcing collaboration with Steno Diabetes Center to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD) in first expansion for KidneyIntelX platform beyond US | Renalytix Plc (RNLX) develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. | In the pre-market this morning, the company announced a collaboration with the Steno Diabetes Center, Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). | The initial focus of the collaboration will be on developing a roadmap for implementation of KidneyIntelX at the Steno Diabetes Center and affiliated practices. | Through this collaboration Renalytix and Steno will investigate core elements necessary for successful clinical translation of KidneyIntelX in a European context. Importantly, this is expected to launch the first use of Renalytix's KidneyIntelX platform outside the US to showcase the clinical utility in the EU by utilizing advanced technology to provide better informed care for solving chronic kidney disease. | Steno Diabetes Center Copenhagen, which offers tailored diabetes treatment for people with diabetes, has been at the forefront of innovation in diabetes care since its inception and has been proclaimed by the World Economic Forum to be a world-leading role model from which other countries and healthcare systems can learn. | RNLX trade up over 50% in the pre-market in reaction to the news. | | The $0.44 area has acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $0.50, $0.59 and then the pre-market high at $0.62. Beyond that, $0.68, $0.80, $0.90 and $1 come into play. | Below $0.44, targets to the downside are $0.41, $0.35 and then a gap fill at $0.3019. | | CYN - Up over 40% in pre after announcing the expansion of its dealer network to include Alta Equipment Group, a company with more than $1bn in annual sales | Cyngn Inc. (CYN) an autonomous vehicle (AV) technology company, develops autonomous driving software. | In the pre-market this morning, the company announced the expansion of its dealer network to include Alta Equipment Group, a company with more than $1bn in annual sales. | Alta Equipment Group, the purveyor of both construction and material handling equipment will begin selling Cyngn's autonomous DriveMod Tugger. The DriveMod Tugger bundles Cyngn's autonomous vehicle technology with Motrec's MT-160. | | "Alta has an impressive record of sales, and we are thrilled to have Cyngn's autonomous vehicles included in their catalog," said Lior Tal, CEO of Cyngn. | Shares of CYN traded over 40% higher in the pre-market in reaction to the news. | | $6.25 acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $6.82, $7, and then the pre-market high at $7.44. Beyond that, $8.33 and $9 come into play. | Below $6.25, targets to the downside are $6, $5.50, $4.50, $4 and then $3.96. | | | QS - Up over 40% in pre after agreement with Volkswagen's battery unit PowerCo to massively ramp up production of solid-state batteries pending technological progress and certain royalty payments | QuantumScape Corporation (QS) is a research and development stage company that focuses on the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. | In the pre-market this morning the company announced a landmark agreement with Volkswagen's battery unit PowerCo to massively ramp up production of solid-state batteries pending technological progress and certain royalty payments. | Upon satisfactory technical progress and certain royalty payments, QuantumScape will grant PowerCo the license to mass produce battery cells based on QuantumScape's technology platform. | QS traded up over 40% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $7.98. | Beyond that $9.35, $10, $10.25 and $11 come into play. | Below $7.98, targets to the downside are $7.10, $6.90, $6.65, $6.25, $6, $5.50 and then a gap fill at $5.41. | | MARKET NEWS 📰 | | | 👊 Make sure you are getting my mobile text alerts – text "RAGE" to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the "1" at the front!). Don't miss out! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | *Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." | Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on July 11, 2024. Previously, we received fifteen thousand dollars via ach bank transfer by Lifewater Media for advertising Citius Pharmaceuticals for a one marketing program on March 9th, 2023. These amounts were paid by someone else not connected to Citius Pharmaceuticals. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. | Now, diving right into Citius Pharmaceuticals might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, | Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep's with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
Tidak ada komentar:
Posting Komentar